---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032455"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-10-09T21:15:50+00:00"
generated_at: "2026-10-12T14:59:05.678318+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin shareholders approve reverse split authority up to 1-for-20; supermajority removal fails

## Summary
- Shareholders approved board authority for a reverse stock split at a ratio of 1-for-2 to 1-for-20, exercisable before the one-year anniversary of the Oct. 9, 2026 annual meeting.
- Amendment to eliminate supermajority charter-voting requirements failed, falling short of the required two-thirds of outstanding shares (2,828,497 for, 901,488 against).
- Stockholders approved an amendment to the 2024 Stock Plan adding 3,861,894 shares; the 8-K states 3,875,999 shares total authorized for issuance.
- Re-elected directors Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak; Grant Thornton LLP ratified as auditor for fiscal 2026 and say-on-pay passed.

## SEC filing metadata
- accession: 0001437749-26-032455
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-10-09T21:15:50+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/0001437749-26-032455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/mbrx20261009_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032455
- JSON: https://secwatch.observer/filing/0001437749-26-032455.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.